 Design: This is a Phase I, non-randomized, prospective, uncontrolled single-center study to evaluate subconjunctival sirolimus as a treatment for active anterior uveitis. All participants will receive a single 30-microL 1,320 microg subconjunctival sirolimus injection in the study eye at baseline and will be followed for 16 weeks post-injection. 